Loading
A phase 2 trial of BH3 profiling in Oesophageal cancer and Oesophageal and junctional adenocarcinoma, run by National Cancer Institute (NCI), recorded as terminated on the registry.
Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy is a phase 2 interventional study registered as NCT03223662 by National Cancer Institute (NCI), with 2 participants recorded, started 2017-10-31 and due to reach its primary completion in 2018-07-27. Interventions recorded: Chemoradiotherapy, Esophagectomy. Conditions recorded: Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Esophageal Neoplasms, Squamous Cell Carcinoma.
Linked to the technology BH3 profiling because the registry's title names it ("bh3 profiling") and Oesophageal cancer and Oesophageal and junctional adenocarcinoma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer and the tag pipeline.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer and the tag pipeline.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer and the tag pipeline.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer and the tag pipeline.
Shares Oesophageal and junctional adenocarcinoma and the tag pipeline.
Shares Oesophageal cancer and the tag pipeline.
Shares Oesophageal cancer and the tag pipeline.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/